Table 2.
Efficacy comparison of PARPi/ICI combination therapy with single agents.
| Cancer | Clinical trials | Drugs | ORR, % | DCR, % | mPFS, mo | mOS, mo | References |
|---|---|---|---|---|---|---|---|
| TNBC | NCT02657889 | Niraparib + pembrolizumab | Total: 21 BRCA+: 47 BRCA−: 11 PD-L1+: 32 PD-L1−: 8 |
Total: 49 BRCA+: 80 BRCA−: 33 |
Total: 2.3 BRCA+: 8.3 BRCA−: 2.1 |
NA | Vinayak et al90 |
| NCT01848834 | Pembrolizumab | 18.5 | 25.9 | 1.9 | 11.2 | Nanda et al99 | |
| NCT02447003 | Pembrolizumab | PD-L1+: 5.3 PD-L1−: 5.7 |
PD-L1+: 7.6 PD-L1−: 9.5 |
2.0 | 9.0 | Adams et al100 | |
| NCT00749502 | Niraparib | BRCA+: 5 | NA | NA | NA | Sandhu et al15 | |
| Ovarian cancer | NCT02657889 | Niraparib + pembrolizumab | Total: 18 BRCA+: 18 BRCA−: 19 PD-L1+: 21 PD-L1−: 10 |
65 | 3.4 | NA | Konstantinopoulos et al89 |
| NCT02674061 | Pembrolizumab | 9.9 | 37.4 | 2.1 | 17.6 | Cohort B101 | |
| NCT02054806 | Pembrolizumab | 11.5 | NA | 1.9 | 13.1 | Varga et al102 | |
| SCLC | NCT02484404 | Olaparib + durvalumab | 10.5 | NA | 1.8 | 4.1 | Thomas et al56 |
| NCT02734004 | Olaparib + durvalumab | 11 | 29 | NA | NA | Krebs et al92 | |
|
NCT02054806 NCT02628067 |
Pembrolizumab | 19.3 | 37.4 | 2.0 | 7.7 | Chung et al103 | |
| NCT01928394 | Nivolumab | 10 | 32 | NA | 4.4 | Antonia et al104 | |
| mCRPC | NCT02484404 | Olaparib + durvalumab | 23.5 | 70.6 | 16.1 | NA | Karzai et al96 |
| NCT02787005 | Pembrolizumab | 5 | 10 | 2.1 | 9.6 | Antonarakis et al97 |
Abbreviations: BRCA, breast cancer susceptibility gene; DCR, disease control rate; ICI, immune checkpoint inhibitor; mCRPC, metastatic castration-resistant prostate cancer; mOS, median overall survival; mPFS, median progression-free survival; ORR, objective response rate; PARPi, poly (ADP-ribose) polymerase inhibitors; PD-L1, programmed cell death ligand 1; SCLC, small cell lung cancer; TNBC, triple-negative breast cancer.